Skip to main content

Table 1 Myelodysplastic syndrome disease characteristics of patients treated with ezatiostat and analyzed by Illumina expression arrays

From: Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome

Baseline Cytopenia Illumina # Response Sex Age Hgb WBC ANC Platelets WHO IPSS Blasts (%) Karyotype
E only TLK-1 NR F 69 9.3 4.4 3.08 325 RARS Int-1 1 46,XX,del(11)(q14q23)[11]/46,XX[9]
E only TLK-10 NR F 84 7.7 3.7 2.07 324 RAEB-2 Int-1 10 NA
E only TLK-11 NR M 53 11 9.7 7,00 310 RA Int-1 2 47,XY[19]
E only TLK-12 NR M 81 8.9 4..1 2.10 343 RA Low 1 45,X,-Y[4]/46,XY[16]
EN TLK-13 NR F 72 10 1.6 0.58 113 RAEB-1 Int-1 6 46,XX[19]
P only TLK-14 NR M 76 12 1.7 1.27 94 RA Low 1 45,X,-Y[19]
E only TLK-15 NR F 67 6.2 1.8 1.08 133 RA Low 3-5 46,XX[19]
NP TLK-16 NR F 68 12.2 3.2 1.05 73 RA Low <5 46,XX[19]
EN TLK-2 NR M 67 10 2.8 1.232 120 RA Int-1 1 46,XY[20]
EP TLK-21 NR M 63 10 3.2 0.64 76 RA Int-1 <5 46,XY[19]
E only TLK-27 NR F 73 9.2 4.6 3.22 221 RARS Int-1 0-1 46,XX,der(7)t(1;7)(q25;36) ort(1;7)(q23;q32)[5]/46,Xdel(X)(q24q28),der(7)t(1;7)(q25;q36) ort(1;7)(q23;q32)[15]
N only TLK-28 NR M 67 14 3.2 0.99 108 RARS NA NA 46,XY[19]
ENP TLK-29 NR F 74 10.8 3.7 1.27 56 RA Int-1 1 46,XX,dup(1)(q21q42)[16]/46,XX[4]
E only TLK-3 NR M 71 8.9 2.1 1.39 108 RA Low 0-1 46,XY[19]
EP TLK-30 NR M 79 10 3.17 3.36 101 RA Low 1 46,XY,del(20)(q11.2q13.3)[19]
P only TLK-4 NR M 77 13 3.3 2.25 93 RA Int-1 0 46,XY-20,+/der(20)del(20)(p12)del(20) (q11.2)[21]
E only TLK-5 NR M 81 7.8 10.8 7.88 157 RARS Low 2 46,XY,del(2)(p13),inv(5)(q13q33),add(13)(q22)[7]/46,XY,del(5)(q13q33)[3],/add(13)(q22)[3]/46,XY[10]
E only TLK-6 NR M 73 10 3.9 3 289 RA Low 1 46,XY[20]
E only TLK-7 NR F 67 11 8.3 3.74 251 RARS Int-1 1-2 47,XX,+8[14]/46,XX[6]
NP TLK-8 NR M 75 12 2.9 1.22 104 RA Int-1 1 44,XY,del(3)(p12p21),-5-9,add(13)(p11.2)[5]/44,X,-Y,del(3)(p12p21),del(5)(q13q33),add (6)(q21),-9,-12,add(13)(p11.2),+mar[2]/43,sdl118 [2]/43,sdl2,add(7)(q22)[6]/46,XY[5]
E only TLK-9 NR M 77 9.1 4 2.6 253 RARS Low 1 46,XY[19]
ENP TLK-17 R F 66 8.7 2 0.34 90 RARS Int1 3 46,XX[19]
E only TLK-18 R M 80 9.3 2.7 1.9 168 RA Low 4 46,XY[19]
ENP TLK-19 R M 79 10 3.3.. 0.79 98 RAEB-1 Int-1 4 46,XY,t(2;3)(p15;q27)[11]/46,XY [9]
EN TLK-20 R M 68 9.7 2.8 0.67 336 RARS Low 2 46,XY[19]
P only TLK-22 R M 71 11 5.64 3.38 35 RA Low 1 46,XY[19]
NP TLK-23 R F 71 13 2.6 1.48 106 RA Int-1 0-1 46,XX,-9,del(11)(q13),+mar[22]/46,XX[2]
EP TLK-24 R M 81 9.2 5.6 3.02 148 RA Low 1 45,X,-Y[11]/46,XY[9]
EP TLK-25 R M 79 11 3.7 1 68 RAEB-1 Int-1 5 46,XY[19]
NP TLK-26 R F 75 13 3.6 1.26 39 RA Low 3 46,XX[19]
  1. Abbreviations: ANC absolute neutrophil count, E erythroid, F female, Hgb hemoglobin, Int-1 International-1, IPSS International Prognostic Scoring System, M male, N neutrophil, NR nonresponder, P platelet, R responder, RA refractory anemia, RAEB-1 refractory anemia with excess blasts type 1, RAEB-2 RA with excess blasts type 2, RARS refractory anemia with ringed sideroblasts, WBC white blood count, WHO World Health Organization.